Tom Vink

4.8k total citations · 2 hit papers
34 papers, 3.6k citations indexed

About

Tom Vink is a scholar working on Radiology, Nuclear Medicine and Imaging, Hematology and Molecular Biology. According to data from OpenAlex, Tom Vink has authored 34 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 16 papers in Hematology and 8 papers in Molecular Biology. Recurrent topics in Tom Vink's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Platelet Disorders and Treatments (12 papers) and Blood groups and transfusion (9 papers). Tom Vink is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Platelet Disorders and Treatments (12 papers) and Blood groups and transfusion (9 papers). Tom Vink collaborates with scholars based in Netherlands, Germany and United States. Tom Vink's co-authors include Paul W.H.I. Parren, Jan G. J. van de Winkel, Wim K. Bleeker, Jerry W. Slootstra, Janine Schuurman, Matthias Peipp, Thomas Valerius, Rob C. Aalberse, Tamara H. den Bleker and Pilar Martínez‐Martínez and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Tom Vink

34 papers receiving 3.5k citations

Hit Papers

Daratumumab, a Novel Ther... 2007 2026 2013 2019 2010 2007 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
    2010 746 citations Tom Vink, Matthias Peipp et al. The Journal of Immunology profile →
  2. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
    2007 707 citations Janine Schuurman, Mario Losen et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Tom Vink 1.3k 1.2k 1.1k 1.0k 854 34 3.6k
Elizabeth A. Wayner 1.0k 0.8× 2.2k 1.8× 1.1k 0.9× 1.3k 1.3× 614 0.7× 57 6.2k
Jean‐Louis Preud'homme 818 0.6× 1.5k 1.2× 784 0.7× 1.6k 1.6× 463 0.5× 99 4.2k
W. Michael Gallatin 656 0.5× 1.9k 1.6× 694 0.6× 1.9k 1.9× 602 0.7× 41 4.7k
G Chi-Rosso 785 0.6× 1.5k 1.2× 608 0.5× 1.6k 1.6× 337 0.4× 27 4.2k
Sherman Fong 1.2k 0.9× 809 0.7× 228 0.2× 1.7k 1.7× 443 0.5× 81 3.4k
Edward D. Ball 294 0.2× 1.2k 1.0× 1.1k 1.0× 1.3k 1.3× 1.2k 1.5× 176 3.5k
Fedor Berditchevski 440 0.3× 2.7k 2.2× 958 0.8× 1.1k 1.1× 729 0.9× 72 5.5k
Henrik E. Mei 494 0.4× 716 0.6× 330 0.3× 2.1k 2.1× 374 0.4× 56 3.7k
Michael R. Robinson 1.4k 1.0× 1.2k 0.9× 321 0.3× 2.4k 2.4× 2.4k 2.8× 110 6.4k
Alec M. Cheng 321 0.2× 1.7k 1.4× 437 0.4× 2.0k 2.0× 545 0.6× 28 3.9k

Countries citing papers authored by Tom Vink

Since Specialization
Citations

This map shows the geographic impact of Tom Vink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Vink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Vink more than expected).

Fields of papers citing papers by Tom Vink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Vink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Vink. The network helps show where Tom Vink may publish in the future.

Co-authorship network of co-authors of Tom Vink

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Vink. A scholar is included among the top collaborators of Tom Vink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Vink. Tom Vink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Losen, Mario, Aran F. Labrijn, Vivianne van Kranen-Mastenbroek, et al.. (2017). Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Scientific Reports. 7(1). 992–992. 8 indexed citations
2.
Goeij, Bart E.C.G. de, Tom Vink, Esther C.W. Breij, et al.. (2016). Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63. Molecular Cancer Therapeutics. 15(11). 2688–2697. 101 indexed citations
3.
4.
Rose, Rebecca, Patrick H.C. van Berkel, Ewald T.J. van den Bremer, et al.. (2013). Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. mAbs. 5(2). 219–228. 53 indexed citations
5.
Vink, Tom, et al.. (2013). A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 65(1). 5–10. 102 indexed citations
6.
Overdijk, Marije B., Sandra Verploegen, Antonio Ortiz Buijsse, et al.. (2012). Crosstalk between Human IgG Isotypes and Murine Effector Cells. The Journal of Immunology. 189(7). 3430–3438. 157 indexed citations
7.
Berkel, Patrick H.C. van, et al.. (2009). N‐linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnology Progress. 25(1). 244–251. 62 indexed citations
8.
Berkel, Patrick H.C. van, et al.. (2009). Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. Biotechnology and Bioengineering. 105(2). 350–357. 33 indexed citations
9.
Peipp, Matthias, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck, et al.. (2008). Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 112(6). 2390–2399. 169 indexed citations
10.
Teeling, Jessica L., Wendy J.M. Mackus, Stephen A. Beers, et al.. (2006). The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20. The Journal of Immunology. 177(1). 362–371. 466 indexed citations
11.
Adan, Roger A.H., Jacquelien J Hillebrand, Wouter A.J. Nijenhuis, et al.. (2003). Melanocortin System and Eating Disorders. Annals of the New York Academy of Sciences. 994(1). 267–274. 25 indexed citations
12.
Vink, Tom, Anke Hinney, Annemarie Elburg, et al.. (2001). Association between an agouti-related protein gene polymorphism and anorexia nervosa. Molecular Psychiatry. 6(3). 325–328. 132 indexed citations
13.
Adan, Roger A.H. & Tom Vink. (2001). Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders. European Neuropsychopharmacology. 11(6). 483–490. 20 indexed citations
14.
Lankhof, H., Marion E. Schiphorst, Martin J. W. IJsseldijk, et al.. (1997). von Willebrand Factor without the A2 Domain Is Resistant to Proteolysis. Thrombosis and Haemostasis. 77(5). 1008–1013. 24 indexed citations
15.
Lankhof, H., Marion E. Schiphorst, Martin J. W. IJsseldijk, et al.. (1997). Functional Studies on Platelet Adhesion With Recombinant von Willebrand Factor Type 2B Mutants R543Q and R543W Under Conditions of Flow. Blood. 89(8). 2766–2772. 29 indexed citations
16.
Lankhof, H., Marion E. Schiphorst, Madelon Bracke, et al.. (1996). A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III. Thrombosis and Haemostasis. 75(6). 950–958. 121 indexed citations
17.
18.
19.
20.
Vijgenboom, Erik, Tom Vink, Barend Kraal, & Ludo Van Den Bosch. (1985). Mutants of the elongation factor EF-Tu, a new class of nonsense suppressors.. The EMBO Journal. 4(4). 1049–1052. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth A. Wayner Breakdown of academic impact, for papers by Jean‐Louis Preud'homme Breakdown of academic impact, for papers by W. Michael Gallatin Breakdown of academic impact, for papers by G Chi-Rosso Breakdown of academic impact, for papers by Sherman Fong Breakdown of academic impact, for papers by Edward D. Ball Breakdown of academic impact, for papers by Fedor Berditchevski Breakdown of academic impact, for papers by Henrik E. Mei Breakdown of academic impact, for papers by Michael R. Robinson Breakdown of academic impact, for papers by Alec M. Cheng
Rankless by CCL
2026